Baseline HDL Cholesterol and the Anti-VEGF Injection-Sparing Effect of an SGLT2 Inhibitor in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.

Ishibashi R, Koshizaka M, Hirayama K, Sakai T, Tatsumi T, Takatsuna Y, Baba T, Maezawa Y, Yokote K.

Open source

DOI
10.1111/dom.71223
Published
2026-08-18
Container
Diabetes Obes Metab
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/dom.71223,
  title = {Baseline HDL Cholesterol and the Anti-VEGF Injection-Sparing Effect of an SGLT2 Inhibitor in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.},
  author = {Ishibashi R and  Koshizaka M and  Hirayama K and  Sakai T and  Tatsumi T and  Takatsuna Y and  Baba T and  Maezawa Y and  Yokote K.},
  year = {2026},
  journal = {Diabetes Obes Metab},
  doi = {10.1111/dom.71223},
  url = {https://doi.org/10.1111/dom.71223}
}

RIS

TY  - JOUR
TI  - Baseline HDL Cholesterol and the Anti-VEGF Injection-Sparing Effect of an SGLT2 Inhibitor in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.
AU  - Ishibashi R
AU  -  Koshizaka M
AU  -  Hirayama K
AU  -  Sakai T
AU  -  Tatsumi T
AU  -  Takatsuna Y
AU  -  Baba T
AU  -  Maezawa Y
AU  -  Yokote K.
PY  - 2026
JO  - Diabetes Obes Metab
DO  - 10.1111/dom.71223
UR  - https://doi.org/10.1111/dom.71223
ER  - 

APA

R, I., M, K., K, H., T, S., T, T., Y, T., T, B., Y, M., & K., Y. (2026). Baseline HDL Cholesterol and the Anti-VEGF Injection-Sparing Effect of an SGLT2 Inhibitor in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.. Diabetes Obes Metab. https://doi.org/10.1111/dom.71223

Source records